Neuroimmune predictors of outcome after aneurysmal subarachnoid hemorrhage

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Aim. To determine the possibility of predicting the course and outcomes of aneurysmal subarachnoid hemorrhage (aSAH) by using the detection of autoantibody level to neurospecific proteins.

Methods. The autoantibody level to neurospecific proteins was detected in 65 people: 30 healthy volunteers and 35 with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage. Autoantibodies to myelin basic protein (MBP), peripheral myelin, dopamine receptors, myosin, N-methyl-D-aspartate (NMDA) receptors and S100 protein detected by using an enzyme immunoassay. The severity of illness in dynamics was defined in all patients by using the following scales: Rivermead mobility index, Hunt–Hess, Graeb and others. Statistical analysis was performed using Statistica 10.0, with the consistent use of descriptive statistics methods, the Mann–Whitney, Kruskal–Wallis and Pearson tests, Spearman coefficient.

Results. At the first stage, neurospecific proteins characterized by a large increase in autoantibody titers were identified. Further, based on the data obtained, a statistically significant correlation between autoantibody ­titers to S100 protein (360.43±40.35 µg/ml, p <0.05), MBP (145.91±12.43 µg/ml, p <0.05), NMDA receptors (66.17±6.42 µg/ml, p <0.05) and aSAH outcome was established.

Conclusion. The study revealed an increase in autoantibody level to neurospecific proteins in the blood plasma of patients, depending on the severity of subarachnoid hemorrhage and the development of delayed cerebral ischemia due to cerebral vasospasm; high antibodies titers to S100 protein in subarachnoid hemorrhage are associated with cerebral vasospasm and the development of secondary (delayed) ischemic changes in the brain.


Full Text

Restricted Access

About the authors

S V Ermakov

Stavropol Regional Clinical Hospital

Author for correspondence.
Email: s.v.yermakov@yandex.ru

Russian Federation, Stavropol, Russia

S M Karpov

Stavropol State Medical University

Email: s.v.yermakov@yandex.ru

Russian Federation, Stavropol, Russia

V A Вaturin

Stavropol State Medical University

Email: s.v.yermakov@yandex.ru

Russian Federation, Stavropol, Russia

O S Belokon

Stavropol Regional Clinical Hospital

Email: s.v.yermakov@yandex.ru

Russian Federation, Stavropol, Russia

R A Mozheiko

Stavropol Regional Clinical Hospital; Stavropol State Medical University

Email: s.v.yermakov@yandex.ru

Russian Federation, Stavropol, Russia; Stavropol, Russia

References

  1. Golovina N.P., Lavrov U.V., Kutashov V.A., Sazonov J.E. Cerebral stroke: a modern view on the problem. Prikladnye informatsionnye aspekty meditsiny. 2015; 18 (5): 56–62. (In Russ.)
  2. Baturin V.A., Baturina M.V., Mamtseva G.I., Boev O.I. et al. Levels of neurotropic autoantibodies in patients with schizophrenia. Meditsinsky vestnik Severnogo Kavkaza. 2016; 11 (2): 176–178. (In Russ.) doi: 10.14300/mnnc.2016.11030.
  3. D’Souza S. Aneurysmal subarachnoid hemorrhage. Neurosurg. Anesth. 2015; 27 (3): 22–40. doi: 10.1097/ANA.0000000000000130.
  4. Kerz T., Boor S., Ulrich A. et al. Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage. Brit. J. Neurosurg. 2016; 30 (5): 49–53. doi: 10.3109/02688697.2016.1173193.
  5. Becker K. Modulation of the postischemic immune response to improve stroke outcome. Stroke. 2010; 41: 75–78. doi: 10.1161/STROKEAHA.110.592881.
  6. Sanchez-Pena P., Pereira A.-R., Sourour N.-A. et al. S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit. Care Med. 2008; 36 (8): 2267–2273. doi: 10.1097/CCM.0b013e3181809750.
  7. Belokon O.S., Ermakov S.V., Karpov S.M. et al. To the choice of surgical treatment of cerebral angiospasm in patients with aneu­rismatic subarachnoid hemorrhage. Meditsinskii vestnik Severnogo Kavkaza. 2020; 15 (1): 119–120. (In Russ.) doi: 10.14300/mnnc.2020.15028.
  8. Hop J.W., Rinkel G.J., Algra A. et al. Case-fatali­ty rates and functional outcome after subarachnoid hemor­rhage: A systematic re-view. Stroke. 1997; 28: 660–664. doi: 10.1161/01.str.28.3.660.
  9. Yong-Ke Zheng, Xiao-Qiao Dong, Quan Du. Comparison of plasma copeptin and multiple biomarkers for assessing prognosis of patients with aneurysmal subarachnoid hemorrhage. Clin. Chim. Acta. 2017; 465: 64–69. doi: 10.1016/j.cca.2017.10.009.
  10. Ayvazyan V.A., Boyadzhyan V.S., Manukyan L.A. et al. Komponenty sistemy komplementa C3 i factor B v krovi bol'nykh s ostrym ishemicheskim insul'tom. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Prilozhenie Insul't. 2005; (15): 57–60. (In Russ.)
  11. Amantea D., Nappi G., Bernardi G. et al. Post-ische­mic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 2009; 276 (1): 13–26. doi: 10.1111/j.1742-4658.2008.06766.x.

Supplementary files

Supplementary Files Action
1.
Рис. 1. Уровни аутоантител к нейроспецифическим белкам в норме и при субарахноидальном кровоизлиянии; ОБМ — основной белок миелина; NMDA — N-метил-D-аспартат-рецепторы

Download (17KB) Indexing metadata
2.
Рис. 2. Зависимость уровня аутоантител (ауто-АТ) к белку S100 от тяжести субарахноидального кровоизлияния

Download (13KB) Indexing metadata
3.
Рис. 3. Зависимость уровня аутоантител (ауто-АТ) к NMDA-рецепторам от тяжести субарахноидального кровоизлияния (САК)

Download (13KB) Indexing metadata
4.
Рис. 4. Средние значения уровня аутоантител (ауто-АТ) к белку S100 у пациентов с различной выраженностью церебрального ангиоспазма (ЦА)

Download (15KB) Indexing metadata
5.
Рис. 5. Средние значения уровня аутоантител (ауто-АТ) к NMDA-рецепторам у пациентов с различной выраженностью развития церебрального ангиоспазма (ЦА)

Download (14KB) Indexing metadata

Statistics

Views

Abstract - 37

PDF (Russian) - 5

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


© 2020 Ermakov S.V., Karpov S.M., Вaturin V.A., Belokon O.S., Mozheiko R.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies